Progress on Alzheimer’s Disease stagnating, warns Alzheimer Disease International CEO Paola Barbarino
While stopping the progression of Alzheimer’s disease is not yet possible, hope is on the horizon in the form of new breakthroughs in diagnostics and new treatments. Yet scientific advances alone are not enough; public awareness, clinical practice and healthcare systems across the world must evolve in-step with scientific progress to drive confidence in what can now be achieved and deliver meaningful change for those affected.
It is estimated that over 7 million people are living with Alzheimer’s Disease in Europe, and there is increasing concern about the ability to combat the disease with Europe’s ageing population.
This is the first in a series of independent articles supported by Eli Lilly, in which Euractiv explores the state of play with Alzheimer’s Disease in an interview with Alzheimer's Disease International CEO Paola Barbarino.
Tags in this Article:
Related articles
Improving Early Detection and Diagnosis of Alzheimer’s disease
Research has undisputably shown that the key to preventing or delaying the cognitive decline associated with Alzheimer’s disease (AD) lies in early and accurate detection and diagnosis. Through this, patients can be provided with the opportunity to receive the right treatment at the right time. Not only can this improve their quality of life, but it has the potential to reduce long-term care costs associated with AD.
Alzheimer’s Policy
At Lilly, we’ve remained committed to taking on Alzheimer’s disease (AD) from every angle for the last three decades. Our vision is that in 10 years, timely detection, accurate diagnosis, appropriate treatment and ultimately prevention will be a reality. We are proud to support Alzheimer Europe’s novel #DementiaNeedsEU campaign, which encourages policy makers to prioritise dementia and take concrete steps to ensure that people affected by the condition are supported to live as well as they can.
Lilly Manifesto for Europe Accelerating access and innovation
Lilly invites candidates to endorse a Europe that invests in health and biomedical advances. To welcome innovation, a single conversation is needed, that joins up industrial policy for growth and considers true value of medicines. We call for policies and pragmatic solutions to accelerate access to innovative medicines, improving health outcomes and health system sustainability, and to make Europe a globally competitive hub for the biopharmaceutical industry. Read the full text, by clicking on the pdf link below.